Abstract
Chikungunya (CHIKV) is a re-emerging endemic arbovirus in West Africa. Since July 2023, Senegal and Burkina Faso have been experiencing an ongoing outbreak, with over 300 confirmed cases detected so far in the regions of Kédougou and Tambacounda in Senegal, the largest recorded outbreak yet. CHIKV is typically maintained in a sylvatic cycle in Senegal but its evolution and factors contributing to re-emergence are so far unknown in West Africa, leaving a gap in understanding and responding to recurrent epidemics. We produced, in real-time, the first locally-generated and publicly available CHIKV whole genomes in West Africa, to characterize the genetic diversity of circulating strains, along with phylodynamic analysis to estimate time of emergence and population growth dynamics. A novel strain of the West African genotype, phylogenetically distinct from strains circulating in previous outbreaks, was identified. This suggests a likely new spillover from sylvatic cycles in rural Senegal and potential of seeding larger epidemics in urban settings in Senegal and elsewhere.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been supported by CLIMADE (Climate Amplified Diseases and Epidemics), the National Institute of Health USA (U01 AI151698) for the United World Antivirus Research Network (UWARN), Abbott Laboratories and by NIH NIAID U01AI151698, United World Antiviral Research Network, part of the NIAID CRIED network and WANETAM (West African Network in Tuberculosis AIDS and Malaria). Data analysis support was provided by the Centre for Epidemic Response and Innovation (CERI) at Stellenbosch University. Reagents for WGS were provided by CERI CLIMADE grant from the Rockefeller Foundation (HTH 017). The authors would like to express their gratitude to the Ministry of Health and to Drs. Mamadou Ndiaye, Boly Diop for their support. The authors would like to express their gratitude to the Kedougou District team particularly Dr Fode Danfakha for significant contribution and assistance during this project. The authors would like to express their recognition to the IRESSEF team and CERI group for their commitment during this project and the patients for their participation in this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was reviewed and approved by the Comite National de Ethique pour la Recherche au Senegal (CNERS) (Ref. N 000031/MSAS/CNERS/SP/06/02/2023). All patients who provided consent to give samples for this study were enrolled and samples were collected by staff in the Kedougou district during the 2023 Chikungunya outbreak. The Direction de la Prevention, which is part of the Senegal Ministry of Health, was informed about IRESSEF intervention during Chikungunya outbreak in Senegal on August 8, 2023 with the reference number N/Ref: SM/IRESSEF/RARS/116.09.2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The resulting genomic sequences have been made available on GISAID Epi-Arbo database (EPI_ISL_18498014-EPI_ISL_18498039).